Vincent et al. identified that elevated lysyl oxidase-like 4 (LOXL4) expression in neutrophils contributes to resistance against antiangiogenic therapy in CRC, highlighting a novel role for LOXL4 in neutrophil-driven angiogenesis [47]. This evidence concerns the gene LOXL4 and colorectal carcinoma.